Cover Image
市場調查報告書

創傷性腦損傷:開發平台分析

Traumatic Brain Injury - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213123
出版日期 內容資訊 英文 262 Pages
訂單完成後即時交付
價格
Back to Top
創傷性腦損傷:開發平台分析 Traumatic Brain Injury - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 262 Pages
簡介

創傷性腦損傷,是來自外部的機械性力量造成腦功能的障礙而引發的狀態。通常是對頭部和身體加以打擊和衝擊而產生。有頭痛、暈眩、噁心和嘔吐、心情的變化、疲勞和睡意、睡眠障礙、記憶障礙、集中力缺乏等症狀。治療包含利尿劑、抗痙攣藥、昏睡誘發藥等。

本報告提供創傷性腦損傷的治療藥之開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

創傷性腦損傷概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:大學/研究機別關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機別

開發治療藥的企業

  • ALSP, Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Athersys, Inc.
  • BHR Pharma, LLC
  • Cognosci, Inc.
  • Euroscreen S.A.
  • Grupo Ferrer Internacional, S.A.
  • Karyopharm Therapeutics, Inc.
  • kyorin製藥
  • Levolta Pharmaceuticals, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Lpath, Inc.
  • Luc Therapeutics, Inc.
  • MandalMed, Inc.
  • Mapreg S.A.S.
  • Neuralstem, Inc.
  • Neuren Pharmaceuticals Limited
  • NeuroHealing Pharmaceuticals Inc.
  • NeuroNascent, Inc.
  • Neuronax SAS
  • NeuroVive Pharmaceutical AB
  • New World Laboratories, Inc.
  • Novogen Limited
  • Omeros Corporation
  • PharmatrophiX, Inc.
  • Phylogica Limited
  • Premier Biomedical Inc.
  • Prevacus, Inc.
  • QR Pharma, Inc.
  • RegeneRx Biopharmaceuticals, Inc.
  • Remedy Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • SanBio, Inc.
  • STATegics, Inc.
  • Tetra Discovery Partners LLC
  • vasopharm GmbH
  • VG Life Sciences, Inc.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (levocetirizine dihydrochloride + montelukast sodium)
  • 2-DG
  • ALP-496
  • AMRS-001
  • apomorphine hydrochloride
  • AST-001
  • AST-002
  • AVL-8168
  • Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury
  • CHEC-7
  • CHEC-9
  • CNB-001
  • coenzyme Q10+ cyanocobalamin + cyclobenzaprine hydrochloride + naltrexone + pyridoxine
  • COG-1410
  • cyclosporine
  • dexamethasone acetate + melatonin
  • EPO-Variant
  • ESN-502
  • felbamate
  • FIB-117
  • glyburide
  • HBI-002
  • HBI-137
  • HBN-1
  • HBN-2
  • HPI-201
  • HPI-363
  • ibudilast
  • ICCN-100
  • JM-4
  • KPT-350
  • LB-201
  • LB-205
  • LM11A-31BHS
  • LM22A-4
  • Lpathomab
  • MAP-4343
  • Neu-2000- Drug Profile
  • ND-478
  • NNI-370
  • NNZ-2591
  • NSI-189
  • NSI-566
  • NVP-019
  • NVX-428
  • NWL-53
  • NX-210
  • PF-05285401
  • Posiphen
  • progesterone
  • PRV-002
  • PYC-35
  • PYC-36
  • PYC-38
  • PYC-98
  • R-503
  • RGN-352
  • SB-623
  • sepranolone
  • Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury
  • Small Molecule to Antagonize GPR17 for CNS Disorders
  • Small Molecules for Stroke and Traumatic Brain Injury
  • Small Molecules for Traumatic Brain Injury
  • Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders
  • Small Molecules to Antagonize TLR-4 for CNS Disorders
  • Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases
  • Stem Cell Therapy for Central Nervous System Disorder
  • Stem Cell Therapy for CNS Disorders
  • STSE-15
  • T-094
  • TBI-121
  • TBI-122
  • TBI-123
  • trofinetide
  • UH-0113
  • UH-0213
  • VAS-203
  • VG-1177
  • VitalHeme
  • VOLT-02

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8317IDB

Summary

Global Markets Direct's, 'Traumatic Brain Injury - Pipeline Review, H2 2016', provides an overview of the Traumatic Brain Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury
  • The report reviews pipeline therapeutics for Traumatic Brain Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Traumatic Brain Injury therapeutics and enlists all their major and minor projects
  • The report assesses Traumatic Brain Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Traumatic Brain Injury

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Traumatic Brain Injury Overview
  • Therapeutics Development
    • Pipeline Products for Traumatic Brain Injury - Overview
    • Pipeline Products for Traumatic Brain Injury - Comparative Analysis
  • Traumatic Brain Injury - Therapeutics under Development by Companies
  • Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes
  • Traumatic Brain Injury - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Traumatic Brain Injury - Products under Development by Companies
  • Traumatic Brain Injury - Products under Investigation by Universities/Institutes
  • Traumatic Brain Injury - Companies Involved in Therapeutics Development
    • ALSP, Inc.
    • Amarantus Bioscience Holdings, Inc.
    • Athersys, Inc.
    • Beech Tree Labs, Inc.
    • Cognosci, Inc.
    • Euroscreen S.A.
    • Intellect Neurosciences, Inc.
    • Ischemix, Inc.
    • Karyopharm Therapeutics, Inc.
    • Kyorin Pharmaceutical Co., Ltd.
    • Levolta Pharmaceuticals, Inc.
    • Lixte Biotechnology Holdings, Inc.
    • Lpath, Inc.
    • MandalMed, Inc.
    • Mapreg S.A.S.
    • Neuralstem, Inc.
    • Neuren Pharmaceuticals Limited
    • NeuroNascent, Inc.
    • Neuronax SAS
    • NeuroVive Pharmaceutical AB
    • New World Laboratories, Inc.
    • Novogen Limited
    • NuvOx Pharma LLC
    • Omeros Corporation
    • PharmatrophiX, Inc.
    • Phylogica Limited
    • Prevacus, Inc.
    • QR Pharma, Inc.
    • RegeneRx Biopharmaceuticals, Inc.
    • Remedy Pharmaceuticals, Inc.
    • Sage Therapeutics, Inc.
    • SanBio, Inc.
    • STATegics, Inc.
    • Stemedica Cell Technologies, Inc.
    • SynZyme Technologies, LLC
    • Tetra Discovery Partners LLC
    • Thera Neuropharma Inc
    • vasopharm GmbH
    • VG Life Sciences, Inc.
  • Traumatic Brain Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (levocetirizine dihydrochloride + montelukast sodium) - Drug Profile
    • 2-DG - Drug Profile
    • ALP-496 - Drug Profile
    • AMRS-001 - Drug Profile
    • AST-001 - Drug Profile
    • AST-002 - Drug Profile
    • AVL-8168 - Drug Profile
    • BQ-A - Drug Profile
    • BTL-slo - Drug Profile
    • Cell Therapy for Traumatic Brain Injury - Drug Profile
    • Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile
    • CHEC-7 - Drug Profile
    • CHEC-9 - Drug Profile
    • CMX-2043 - Drug Profile
    • CNB-001 - Drug Profile
    • COG-1410 - Drug Profile
    • cyclosporine - Drug Profile
    • dexamethasone acetate + melatonin - Drug Profile
    • EPO-Variant - Drug Profile
    • ESN-502 - Drug Profile
    • ethinyl estradiol sulfonate - Drug Profile
    • EUC-001 - Drug Profile
    • felbamate - Drug Profile
    • glyburide - Drug Profile
    • HBI-002 - Drug Profile
    • HBI-137 - Drug Profile
    • HBN-1 - Drug Profile
    • HBN-2 - Drug Profile
    • HPI-201 - Drug Profile
    • HPI-363 - Drug Profile
    • ibudilast - Drug Profile
    • ICCN-100 - Drug Profile
    • JM-4 - Drug Profile
    • KPT-350 - Drug Profile
    • LB-201 - Drug Profile
    • LB-205 - Drug Profile
    • LM-22A4 - Drug Profile
    • LM11A-31BHS - Drug Profile
    • Lpathomab - Drug Profile
    • MAP-4343 - Drug Profile
    • Monoclonal Antibody for Central Nervous System - Drug Profile
    • N-acetyl cysteine amide - Drug Profile
    • ND-478 - Drug Profile
    • Neu-2000 - Drug Profile
    • neuregulin-1 - Drug Profile
    • NNI-370 - Drug Profile
    • NNZ-2591 - Drug Profile
    • NSI-189 - Drug Profile
    • NSI-566 - Drug Profile
    • NVP-019 - Drug Profile
    • NVX-428 - Drug Profile
    • NWL-53 - Drug Profile
    • NX-210 - Drug Profile
    • PF-05285401 - Drug Profile
    • Posiphen - Drug Profile
    • PRV-002 - Drug Profile
    • PYC-35 - Drug Profile
    • PYC-36 - Drug Profile
    • PYC-38 - Drug Profile
    • PYC-98 - Drug Profile
    • R-503 - Drug Profile
    • RGN-352 - Drug Profile
    • ronopterin - Drug Profile
    • SanFlow - Drug Profile
    • SB-623 - Drug Profile
    • sepranolone - Drug Profile
    • Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
    • Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile
    • Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile
    • Small Molecules for Traumatic Brain Injury - Drug Profile
    • Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
    • Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile
    • Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
    • Stem Cell Therapy for Central Nervous System Disorder - Drug Profile
    • Stem Cell Therapy for CNS Disorders - Drug Profile
    • STSE-15 - Drug Profile
    • SYN-2 - Drug Profile
    • SYN-NCE - Drug Profile
    • T-094 - Drug Profile
    • TauC-3 - Drug Profile
    • UH-0113 - Drug Profile
    • UH-0213 - Drug Profile
    • VG-1177 - Drug Profile
    • VitalHeme - Drug Profile
    • VOLT-02 - Drug Profile
    • ZL-006 - Drug Profile
  • Traumatic Brain Injury - Dormant Projects
  • Traumatic Brain Injury - Discontinued Products
  • Traumatic Brain Injury - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Traumatic Brain Injury, H2 2016
  • Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Traumatic Brain Injury - Pipeline by ALSP, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Athersys, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Beech Tree Labs, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Cognosci, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Euroscreen S.A., H2 2016
  • Traumatic Brain Injury - Pipeline by Intellect Neurosciences, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Ischemix, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Lpath, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by MandalMed, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Mapreg S.A.S., H2 2016
  • Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H2 2016
  • Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Neuronax SAS, H2 2016
  • Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2016
  • Traumatic Brain Injury - Pipeline by New World Laboratories, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Novogen Limited, H2 2016
  • Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H2 2016
  • Traumatic Brain Injury - Pipeline by Omeros Corporation, H2 2016
  • Traumatic Brain Injury - Pipeline by PharmatrophiX, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Phylogica Limited, H2 2016
  • Traumatic Brain Injury - Pipeline by Prevacus, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by SanBio, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by STATegics, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
  • Traumatic Brain Injury - Pipeline by SynZyme Technologies, LLC, H2 2016
  • Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H2 2016
  • Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H2 2016
  • Traumatic Brain Injury - Pipeline by vasopharm GmbH, H2 2016
  • Traumatic Brain Injury - Pipeline by VG Life Sciences, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Traumatic Brain Injury - Dormant Projects, H2 2016
  • Traumatic Brain Injury - Dormant Projects (Contd..1), H2 2016
  • Traumatic Brain Injury - Dormant Projects (Contd..2), H2 2016
  • Traumatic Brain Injury - Dormant Projects (Contd..3), H2 2016
  • Traumatic Brain Injury - Dormant Projects (Contd..4), H2 2016
  • Traumatic Brain Injury - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Traumatic Brain Injury, H2 2016
  • Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top